Pegylated arginine deiminase: A novel anticancer enzyme agent

Expert Opinion on Investigational Drugs

Volumn 15, Issue 7, 2006, Pages 815-822

  Feun, Lynn ^a   Savaraj, Niramol ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Anticancer enzyme; Arginine; Argininosuccinate synthetase expression; Hepatocellular carcinoma; Melanoma

Indexed keywords

ADI PEG20; AMINO ACID; ANTINEOPLASTIC AGENT; ARGININE; ARGININOSUCCINATE SYNTHASE; CITRULLINE; DEXAMETHASONE; HYDROLASE; MACROGOL DERIVATIVE; NEW DRUG; RECOMBINANT PROTEIN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOG; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL MELANOMA; GENETICS; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; MELANOMA; METABOLISM; MOLECULAR GENETICS; MOUSE; MYCOPLASMA HOMINIS; NEOPLASM; NUDE MOUSE; NUTRITIONAL REQUIREMENT; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN TUMOR; SPECIES DIFFERENCE; TREATMENT OUTCOME;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTINEOPLASTIC AGENTS; ARGININE; ARGININOSUCCINATE SYNTHASE; CARCINOMA, HEPATOCELLULAR; CITRULLINE; CLINICAL TRIALS; DEXAMETHASONE; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; DRUGS, INVESTIGATIONAL; HUMANS; HYDROLASES; LIVER NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; MYCOPLASMA HOMINIS; NEOPLASM PROTEINS; NEOPLASMS; NUTRITIONAL REQUIREMENTS; POLYETHYLENE GLYCOLS; RABBITS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SPECIES SPECIFICITY; TREATMENT OUTCOME;

EID: 33747181970     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.7.815     Document Type: Review

References (48)

1. ASSELIN BL: The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. (1999) 457:621-629. (Pubitemid 129735360)
2. MULLER HJ, BOOS J: Use of L-asparaginase in childhood ALL. Crit. Rev. Oncol. Hematol. (1998) 28:97-113. (Pubitemid 28390409)
3. TAKAKU H, TAKASE M, ABE S-I, HAYASHI H, MIYAZAKI K: In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini. Int. J. Cancer (1992) 51:244-249.
4. WHEATLEY DN: Controlling cancer by restricting arginine availability-arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs (2004) 15(9):825-833. (Pubitemid 39482922)
5. WHEATLEY DN: Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells. Semin. Cancer Biol. (2005) 15:247-253. (Pubitemid 41058771)
6. WHEATLEY DN, CAMPBELL E, LAI PBS, CHENG PNM: A rational approach to the systemic treatment of cancer involving medium-term depletion of arginine. Gene Ther. Mol. Biol. (2005) 9:33-40.
7. SCOTT L, LAMB J, SMITH S, WHEATLEY DN: Single amino acid (arginine) deprivation:rapid and selective death of cultured transformed and malignant cells. Br. J. Cancer (2000) 83:800-810. (Pubitemid 30694490)
8. TAKAKU H, MISAWA S, HAYASHI H, MIYAZAKI K: Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini. Jpn J. Cancer Res. (1993) 84:1195-1200. (Pubitemid 23351013)
9. TAKAKU H, MATSUMOT M, MISAWA S, MIYAZAKI M: Anti-tumor activity of arginine deiminase from Mycoplasma arginini and its growth-inhibitory mechanism. Jpn J. Cancer Res. (1995) 86:840-846.
10. SUGIMURA K, OHNO T, FUKUDA S, WADA Y, KIMURA T, AZUMA I: Tumor growth inhibitory activity of a lymphocyte blastogenesis inhibitory factor. Cancer Res. (1990) 50:345-349. (Pubitemid 20041239)
11. SUGIMURA K, OHNO T, KUSUYAMA T, AZUMA I: High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro. Melanoma Res. (1992) 2:191-196.
12. STORR JM, BURTON AF: The effects of arginine deficiency on lymphoma cells. Br J. Cancer (1974) 30:50-59.
13. ENSOR CM, HOLTSBERG FW, BOMALASKI JS, CLARK MA: Pegylated arginine deiminase inhibits humans melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. (2002) 62:5443-5450.
14. GONG H, POTTGEN C, STUBEN G, HAVERS W, STUSCHKE M, SCHWEIGERER L: Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int. J. Cancer (2003) 106:723-728. (Pubitemid 36993396)
15. SZLOSAREK PW, KLABATSA A, PALLASKA A, SHEAFF M, BALKWELL FR, FENNELL D: Arginine depletion upregulates Bax and triggers apoptosis of malignant mesothelioma cells deficient in argininosuccinate synthetase. Proceedings of the American Association of Cancer Research, Washington, DC, USA (2006). (Pubitemid 44974513)
16. LANG PG: Current concepts in the management of patients with melanoma. Am. J. Clin. Dermatol. (2002) 3:401-426. (Pubitemid 34879433)
17. LLOVET JM: Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. (2005) 40: 225-235. (Pubitemid 40613379)
18. LLOVET JM, BRU C, BRUIX J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. (1999) 19:3329-3338 (Pubitemid 29488775)
19. ROGERS QR: Species variation in arginine requirements. Proceedings from a Symposium Honoring Willard J. Visek - from Ammonia to Cancer and Gene Expression, Special Publication 86, Illinois, USA (1994):9-21.
20. CAREY GP, KIME Z, ROGERS QR et al.: An arginine-deficient diet in humans does not evoke hyperammonemia or orotic aciduria. J. Nutr. (1987) 117:1734-1739. (Pubitemid 18015375)
21. BARBUL A: Arginine: biochemistry, physiology, and therapeutic implications. J. Parenteral Enteral Nutr. (1986) 10:227-238. (Pubitemid 16134871)
22. SYNDERMAN SE, BOYER A, HOLT LE Jr: The arginine requirement of the infant. AMA J. Dis. Child. (1959) 97:192-195.
23. ROSE WC: Amino acid requirements of man. Fed. Proc. (1949) 8:546-552.
24. MEHVAR R: Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharmaceut. Sci. (2000) 3:125-136.
25. ZALIPSKY S, LEE C: Use of functionalized poly(ethylene glycol) for modification of polypeptides. In: Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Harris JM (Ed.), Plenum Press, New York, USA (1992):347-370.
26. BOMALASKI JS, IVETT JL, VEGARRA M, HOLTSBERG FW, ENSOR CM, CLARK MA: Comparative toxicity of arginine deiminase formulated with poly(ethylene) glycol 5000 or 20,000 and the effects of arginine. Preclinica (2003) 1:284-293.
27. HOLTSBERG FW, ENSOR CM, STEINER MR, BOMALASKI JS, CLARK MA: Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J. Control Rel. (2002) 80:259-271. (Pubitemid 34273764)
28. ENSOR CM, HOLTSBERG FW, BOMALASKI JS, CLARK MA: Pegylated arginine deiminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. (2002) 62:5443-15440
29. DILLON BJ, PRIETO VG, CURLEY SA et al.: Incidence and distribution of argininosuccinate synthetase deficiency in human cancers. Cancer (2004) 100:826-833.
30. TANG S-W, CHANG W-H, CHAO Y-W et al.: Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library. J. Biomed. Sci. (2006) 13:233-240.
31. NOH E-J, KANG S-W, CHIN LY-J et al.: Arginine deiminase enhances dexamethasone-induced cytotoxicity in human T-lymphoblastic leukemia CCRF-CEM cells. Int. J. Cancer (2004) 112:502-508. (Pubitemid 39390617)
32. CURLEY SA, BOMALASKI JS, ENSOR CM, HOLTSBERG FW, CLARK MA: Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepato-Gastroenterology (2003) 50:1208-1211. (Pubitemid 37186447)
33. IZZO F, MARRA P, BENEDUCE G et al.: Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from Phase I/II studies. J. Clin. Oncol. (2004) 22:1815-1822. (Pubitemid 41095171)
34. DELMAN KA, BROWN TD, THOMAS M et al.: Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma. Proceedings of the American Association of Clinical Oncology, Orlando, USA (2005) 23:342s.
35. CHENG PN, LO TWH, LEUNG TWH et al.: Pegylated recombinant arginase (rh Arg-peg-5000mw) has in vitro and in vivo anti-proliferative potential and apoptotic activities in human hepatocellular carcinoma (HCC). Proceedings of the American Association of Clinical Oncology, Orlando, USA (2005) 23:236s.
36. ASCIERTO PA, SCALA S, CASTELLO G et al.: Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from Phase I and II studies. J. Clin. Oncol. (2005) 23:7660-7668. (Pubitemid 46291831)
37. GONG H, ZOLZER F, VON RECKLINGHAUSEN G et al.: Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem. Biophys. Res. Commun. (1999) 261:10-14. (Pubitemid 29371610)
38. SHEN LJ, LIN W-C, BELOUSSOW K, SHEN WC: Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett. (2006) 231:30-35. (Pubitemid 41779450)
39. FEUN LG, WU C, CLARK M et al.: Mechanism of antitumor effect of arginine deiminase-polyethylene (ADI-PEG20) and the possible mechanism of resistance in melanoma. Proc. Am. Assoc. Can. Res. (2004) 45:.
40. SHEN LJ, LIN WC, BELOUSSOW K, SHEN WC: Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett. (2003) 191:165-170. (Pubitemid 36255601)
41. FEUN LG, SAVARAJ N, MARINI A et al.: Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma. Proc. Am. Soc. Clin. Oncol. (2005)23:236s.
42. ORUCEVIC A, LALA PK: Role of nitric oxide in IL2 therapy-induced capillary leak syndrome. Cancer Metastasis Rev. (1998) 17:127-142. (Pubitemid 28194651)
43. THOMAS JB, HOLTSBERG FW, ENSOR CM et al.: Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin. Biochem. J. (2002) 363:581-587. (Pubitemid 34526379)
44. DILLON BJ, HOLTSBERG FW, ENSOR CM, BOMALASKI JS, CLARK MA: Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production. Med. Sci. Monit. (2002) 8:BR 248-BR 253. (Pubitemid 34826759)
45. KILBOURN RG, FONSECA GA, GRIFFITH OW et al.: NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit. Care Med. (1995) 23:1018-1024.
46. KILBOURN RG, FONSECA GA, TRISSEL LA, GRIFFITH OW: Strategies to reduce side effects of interleukin-2: evaluation of antihypotensive agent NG-monomethyl-L-arginine. Cancer J. Sci. Am. (2000) 6(Suppl. 1):S21-S30. (Pubitemid 30117633)
47. JADESKI LC, HUM KO, CHAKRABORTY C, LALA PK: Nitric oxide promotes murine mammary tumor growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int. J. Cancer (2000) 86:30-39. (Pubitemid 30133983)
48. ZHANG XM, XU Q: Metastatic melanoma cells escape immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res. (2001) 11:559-567. (Pubitemid 33152347)